Safety, tolerability and biological responses of Oreochromis niloticus juveniles upon oral oxolinic acid administration

IF 1.5 4区 农林科学 Q3 PHARMACOLOGY & PHARMACY
Thangapalam Jawahar Abraham, Jaykumar Bhagubhai Patel, Avishek Bardhan, Ravindran Rajisha, Satyen Kumar Panda, Prasanna Kumar Patil
{"title":"Safety, tolerability and biological responses of Oreochromis niloticus juveniles upon oral oxolinic acid administration","authors":"Thangapalam Jawahar Abraham,&nbsp;Jaykumar Bhagubhai Patel,&nbsp;Avishek Bardhan,&nbsp;Ravindran Rajisha,&nbsp;Satyen Kumar Panda,&nbsp;Prasanna Kumar Patil","doi":"10.1111/jvp.13408","DOIUrl":null,"url":null,"abstract":"<p>In aquaculture, oxolinic acid (OA) is used as a second-line treatment at 12 mg/kg biomass/day for seven consecutive days. The present study evaluated the biosafety of 21 days of dietary administration of OA at 0, 12, 36, 60 and 120 mg by assessing the growth, biochemical, erythrocytic morphological and histopathological alterations and residue levels in <i>Oreochromis niloticus</i>. A significant dose-dependent reduction in feed intake and biomass and an increase in mortalities and erythrocytic cellular and nuclear changes were recorded. Significant elevations in plasma glucose, creatinine, alkaline phosphatase, alanine transaminase and aspartate transaminase and a decline in calcium and chloride levels were documented. The kidney, liver and intestine histoarchitecture showed mild to marked alterations. The edible tissue OA residues peaked on day 21 and decreased upon cessation of administration in all the dosing groups. The residue levels in the muscle of the recommended dose group were well within the maximum residue limit set by the European Medicines Evaluation Agency. Although the current study hinted at the safety and tolerability of OA even during long-term usage in <i>O. niloticus</i> in Indian conditions, care must be exercised for its aquacultural application because of its listing as a critically important medicine for humans.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of veterinary pharmacology and therapeutics","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvp.13408","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

In aquaculture, oxolinic acid (OA) is used as a second-line treatment at 12 mg/kg biomass/day for seven consecutive days. The present study evaluated the biosafety of 21 days of dietary administration of OA at 0, 12, 36, 60 and 120 mg by assessing the growth, biochemical, erythrocytic morphological and histopathological alterations and residue levels in Oreochromis niloticus. A significant dose-dependent reduction in feed intake and biomass and an increase in mortalities and erythrocytic cellular and nuclear changes were recorded. Significant elevations in plasma glucose, creatinine, alkaline phosphatase, alanine transaminase and aspartate transaminase and a decline in calcium and chloride levels were documented. The kidney, liver and intestine histoarchitecture showed mild to marked alterations. The edible tissue OA residues peaked on day 21 and decreased upon cessation of administration in all the dosing groups. The residue levels in the muscle of the recommended dose group were well within the maximum residue limit set by the European Medicines Evaluation Agency. Although the current study hinted at the safety and tolerability of OA even during long-term usage in O. niloticus in Indian conditions, care must be exercised for its aquacultural application because of its listing as a critically important medicine for humans.

尼罗罗非鱼幼鱼口服氧吡啶酸的安全性、耐受性和生物学反应。
在水产养殖中,氧吡啶酸(OA)在12岁时被用作二线治疗 mg/kg生物量/天,连续7天。本研究评估了21 0、12、36、60和120时OA饮食给药的天数 mg,通过评估尼罗罗非鱼的生长、生化、红细胞形态和组织病理学变化以及残留物水平。记录到饲料摄入量和生物量的显著剂量依赖性减少,死亡率以及红细胞和细胞核变化的增加。血糖、肌酸酐、碱性磷酸酶、丙氨酸转氨酶和天冬氨酸转氨酶显著升高,钙和氯水平下降。肾脏、肝脏和肠道的组织结构显示出轻度到显著的改变。在所有给药组中,可食用组织OA残留在第21天达到峰值,并且在停止给药时减少。推荐剂量组肌肉中的残留水平完全在欧洲药品评估局设定的最大残留限量范围内。尽管目前的研究表明,即使在印度条件下,OA在尼罗曲霉菌中长期使用也具有安全性和耐受性,但由于其被列为对人类至关重要的药物,因此必须注意其在水产养殖中的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.10
自引率
15.40%
发文量
69
审稿时长
8-16 weeks
期刊介绍: The Journal of Veterinary Pharmacology and Therapeutics (JVPT) is an international journal devoted to the publication of scientific papers in the basic and clinical aspects of veterinary pharmacology and toxicology, whether the study is in vitro, in vivo, ex vivo or in silico. The Journal is a forum for recent scientific information and developments in the discipline of veterinary pharmacology, including toxicology and therapeutics. Studies that are entirely in vitro will not be considered within the scope of JVPT unless the study has direct relevance to the use of the drug (including toxicants and feed additives) in veterinary species, or that it can be clearly demonstrated that a similar outcome would be expected in vivo. These studies should consider approved or widely used veterinary drugs and/or drugs with broad applicability to veterinary species.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信